| NCT ID | NCT04286308 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Massachusetts General Hospital |
| Condition | Parkinson Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2020-10-01 |
| Primary Completion | 2027-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2020-10-01 with a primary completion date of 2027-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this research study the researchers want to learn more about brain activity related to speech perception and production.
Eligibility Criteria
Inclusion Criteria: 1. Subjects scheduled for DBS implantation, as determined by the clinical multidisciplinary movement disorders board with definitive diagnosis of Parkinson's disease, essential tremor or dystonia. 2. Subjects able to provide informed consent and comply with task instructions. 3. Subjects 18-85 years old Exclusion Criteria: 1. Subjects with reported hearing loss. 2. Non-English-speaking subjects
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04286308 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Parkinson Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04286308 currently recruiting?
Yes, NCT04286308 is actively recruiting participants. Contact the research team at mark.richardson@mgh.harvard.edu for enrollment information.
Where is the NCT04286308 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT04286308 clinical trial?
NCT04286308 is sponsored by Massachusetts General Hospital. The trial plans to enroll 80 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.